Prestige Consumer Healthcare Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $4.20B
  • PE 20
  • Debt $1.00B
  • Cash $50.87M
  • EV $5.15B
  • FCF $248.69M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$213.94M
EBIT$330.17M
ROE12%
ROA10%
FCF$248.69M
Equity$1.79B
Growth Stability-48%
PE19.62
PEG4.93
PB2.35
P/FCF16.88
P/S3.75
Price/Cash0.01
Debt/Equity0.56
Debt/FCF4.02
Net Margins20%
Gross Margins55%
Op. Margins30%
Earnings CAGR4%
Sales Growth YoY3%
Sales Growth QoQ2%
Sales CAGR3%
FCF CAGR5%
Equity CAGR11%
Earnings Stability0.09
Earnings Growth YoY15%
Earnings Growth QoQ12%
Earnings CAGR 5Y4%
Sales CAGR 5Y4%
FCF CAGR 5Y3%
Equity CAGR 5Y7%
Earnings CAGR 3Y1%
Sales CAGR 3Y1%
FCF CAGR 3Y2%
Equity CAGR 3Y4%
Market Cap$4.20B
Revenue$1.12B
Assets$3.33B
Total Debt$1.00B
Cash$50.87M
Shares Outstanding49.6M
EV5.15B
Earnings Score7%
Moat Score92%
Safety Score57%
Final Score52%
Working Capital274.62M
Current Ratio3.68
Gross Profit$616.27M
Shares Growth 3y-0%
Equity Growth QoQ3%
Equity Growth YoY12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Prestige Consumer Healthcare is an American company that distributes branded over-the-counter healthcare and household cleaning products to mass merchandisers, drugstores, convenience stores, supermarkets, and e-commerce channels. The firm's major brands include BC/Goody's, Chloraseptic, Clear Eyes, Compound W, Debrox, Dramamine, Fess, Fleet, Gaviscon, Hydralyte, Monistat, Nix, and Summer's Eve. The company's portfolio includes branded products in women's health, gastrointestinal, analgesics, eye and ear care, dermatological products, oral care, skincare, sleep aids, and cough and cold. Its segments include North American OTC Healthcare and International OTC Healthcare.

SEC Filings

Direct access to Prestige Consumer Healthcare Inc. (PBH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-K Mar 31
  • 2023
    • 10-Q Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-K Mar 31
  • 2022
    • 10-Q Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-K Mar 31

Sector Comparison

How does Prestige Consumer Healthcare Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Prestige Consumer Healthcare Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%
Stability 9%
loading chart...

Prestige Consumer Healthcare Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Prestige Consumer Healthcare Inc..

= $3.6B
012345678910TV
fcf$249M$262M$276M$291M$307M$323M$341M$359M$379M$399M$420M$4.2B
DCF$238M$228M$219M$210M$201M$192M$184M$177M$169M$162M$1.6B
Value$3.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024TTM
Net Margins11%12%8%33%-4%15%17%19%-7%19%20%
ROA-9%5%6%2%8%9%9%-1%10%10%
ROE-13%8%29%-3%12%12%13%-6%13%12%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024TTM
Debt over FCF-9.6815.3510.1910.148.617.015.976.134.744.02
Debt over Equity2.542.222.71.711.651.491.10.950.940.690.56
Growth Stability---100%-21%100%100%100%-48%100%-48%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024CAGR 5Y
Revenue YoY growth-13%9%18%-6%-1%-2%15%4%-0%4%
Earnings YoY growth-28%-31%389%-111%-497%16%25%-140%-354%4%
Equity YoY growth-19%11%43%-7%7%16%16%-8%14%7%
FCF YoY growth-14%-15%36%-10%13%5%17%-11%8%3%